1st participant dosed in important new Xanamem study-XanaHES. Actinogen Limited (ASX:ACW)

Thursday, February 21, 2019 9:00 PM +00:00

1st participant dosed in important new Xaname...0:000:00
LIVEQuality1  AudioSubtitleDownloadSpeed1  
ACTINOGEN LIMITED
Bill Ketelbey

Actinogen Medical (ASX: ACW) is pleased to announce dosing of the first participant in XanaHES, a Phase I dose escalation safety study of Xanamem in healthy elderly volunteers. XanaHES is designed to expand the safety data-set for Xanamem, while exploring the potential for higher doses of the drug to be used, if considered necessary, in future trials in Alzheimer's disease and other indications. It is planned that 42 participants will be randomised into the first cohort and receive either 20mg Xanamem or placebo daily for 12 weeks. Following a review of the 20mg safety data, a second cohort of 42 participants may be randomised to receive 30mg Xanamem or placebo daily.


Leave a Comment

Your email address will not be published

WEBCAST Calendar

  • 11 Nov

    02:00

    Elders Limited Investor Teleconference

    ELDERS LIMITED
  • 11 Nov

    02:00

    Altech Chemicals presentation at the 2019 Australian Microcap Investment Conference

    ALTECH CHEMICALS LTD
  • 11 Nov

    02:00

    Petroleum briefing

    BHP BILLITON LIMITED
  • 11 Nov

    02:00

    Q1 FY2020 Investor and Analyst teleconference 8 November 2019

    REA GROUP
  • 11 Nov

    03:00

    Q3 2019 Duke Energy Corporation Earnings Conference Call 08 November 2019

    DUKE ENERGY CORPORATION